OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Are Biopharma Patents Poised on the Post-Grant Chopping Block?
This article examines trends in biopharma post-grant patent review and projects what the future holds in store.
BioPharm International
eBooks Volume 28, Issue 14
Post-grant review of patents at the Patent Trial and Appeal Board (PTAB) has taken the intellectual property (IP) world by storm. Post-grant reviews allow anyone to challenge the validity of a patent far more quickly and cheaply than has ever before been possible. They have replaced the huge financial drain and business risk of traditional patent litigation with a rapid adjudication system that delivers certainty for a price comparable to a patent license fee. Read this article and other articles in
BioPharm International
's 2015
eBook.
